BioPioneer's panel on Biotech Funding 2025: Survive, Adapt, Thrive

Funding isn’t dead, it’s concentrated. We gathered founders, operators, and investors to get tactical about what works now.

Top takeaways

 • Capital concentration: a few are very well funded; many aren’t. Differentiate or die.

 • Stage rotation: Seed → Neuro, Series A → Autoimmune, Series B → Metabolic; Oncology cooled.

 • Platforms must ship assets: Seed aim for in vivo; Series A leads with a standout asset + scalable platform.

 • Operate in wartime: ruthless focus, cash discipline, milestone-driven execution.

 • BD = optionality: extend runway/validation/intel - but don’t sell the crown jewel; beware venture debt & option-to-acquire traps.

 • Ex-US development rising (China, AU, UK/NL, KR/JP): speed/quality/cost-balance with IP & geopolitics.

 • AI with purpose: closed loops + proprietary data win; products > demos.

Action checklist

1. Design seed plans for translation (hit in vivo).

2. Tell the Series A arc now (lead asset first; platform leverage second).

3. Do BD that sits on your strategic vector.

4. Pre-qualify ex-US routes for speed/quality.

5. Use AI where it earns its keep (defensibility = data + IP).

6. Upgrade team “surface area” (operators who’ve shipped).

What gets funded

 • Big problem, clear differentiation/defensibility, and a team that can fundraise and deliver.

 • Best platforms yield the best assets and optionality.

 • In vivo data strongly preferred even at seed.

Milestones by stage

 • Pre-seed: Reproduce academic results; prove the step-change.

 • Seed: Specificity in vitro and confirm in vivo; lock an indication; show velocity.

 • Series A: Lead with therapeutic narrative; show platform scalability.

BD & creative capital

 • Why now: extend runway, signal validation, catalyze term sheets.

 • Risks: partner too early and you cede control/value; avoid off-vector deals.

 • Red flags: venture debt that kills flexibility; option-to-acquire that underpays risk.

 • Do BD when it funds core work, preserves rights/data, and accelerates your plan.

Ex-US development

 • Shift to non-US trials/CMC for cost/speed/quality (China prominent; AU/UK/NL/KR/JP).

 • Caveats: site/data quality, IP, geopolitics.

AI in bio

 • Wins: closed-loop design/build/test, sequence-native models, ops leverage.

 • Defensibility: proprietary data + patents + delivered products.

Teams & fundraising

 • Intangibles matter: ability to raise, recruit, ship. Pair inventors with builders.

 • If you lack data, borrow credibility via co-founders/advisors.

2026 watchlist

 • Hybrid/conjugates (SM-RNA), smarter delivery, in vivo cell therapy, radiopharms.

Gratitude

 Moderator: Max Farina, MD (5AM Ventures)

 Panel: Omri Amirav-Drory (NFX), Sophia Lugo (Radar Therapeutics), Tim Luker (Eli Lilly and Company Ventures)

 Hosts/partners: BioPioneers × MBC BioLabs (Marah Doria, Anthony Hope) × SVB (Matt Donne, PhD)